Skip to main content

Table 3 ODMT discontinuation rates at cumulative post-index time windows of within 3, 6, 9, and 12 months. Because patients had varying durations in their time of follow-up, sample sizes were different for each time window. P-values for medication switching, dose reduction, re-starts, and add-ons were indeterminate, therefore, these data are not shown

From: Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review

Prescribing parameters, n (%)

Total

FTY

DMF

TFN

P-value (3 groups)

(N = 293)

(N = 101)

(N = 133)

(N = 59)

Within 3 months

 Patients, n

281

98

124

59

 

 Discontinuation

12 (4.3)

5 (5.1)

5 (4)

2 (3.4)

0.8629

Within 6 months

 Patients, n

236

79

106

51

 

 Discontinuation

18 (7.6)

5 (6.3)

6 (5.7)

7 (13.7)

0.177

Within 9 months

 Patients, n

188

63

85

40

 

 Discontinuation

25 (13.3)

6 (9.5)

12 (14.1)

7 (17.5)

0.4866

Within 12 months

 Patients, n

151

55

65

31

 

 Discontinuation

22 (14.6)

6 (10.9)

9 (13.8)

7 (22.6)

0.3299

  1. DMF dimethyl fumarate, ODMT oral disease-modifying therapy, FTY fingolimod, TFN teriflunomide